Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021

PUBLISHED ON April 20, 2021

The paper explains research that identified a novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells using the cellular receptor CD320, which is involved in the uptake of Vitamin B12.

read more

Leading Cell Biology Journal Publishes bioAffinity Technologies’ Groundbreaking Research on Porphyrins

PUBLISHED ON March 3, 2021

March 3, 2021 (San Antonio, TX) bioAffinity Technologies, a privately held company focused on early diagnostics and cancer therapeutics, announced that a scientific paper that explains how porphyrins are selectively incorporated into cancer cells has been published in the Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal).

read more

SA biotech pursuing deal to access $5B China market

PUBLISHED ON February 11, 2021

San Antonio Business Journal (February 8, 2021) “China represents a $5 billion market for CyPath© Lung. An estimated 780,000 people will be diagnosed annually in China with lung cancer, most often at late stage,” bioAffinity President and CEO Maria Zannes said. "Fosun Long March is a driving force in health care, bringing medical breakthroughs to China and the world that improve the health and clinical outcomes of patients.”

read more